H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on MediWound (MDWD) to $25 from $28 and keeps a Buy rating on the shares following the Q3 report. The firm says NexoBrid supply may soon meet demand.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDWD: